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Running Title: ApoAI and epithelial cell binding by SOF are functionally discrete 
 
SUMMARY 
Serum opacity factor (SOF) is a unique multi-
functional virulence determinant expressed at the 
surface of S. pyogenes and has been shown to elicit 
protective immunity against GAS infection in a 
murine challenge model. SOF consists of two 
distinct domains with different binding capacities: 
an N-terminal domain which binds apolipoprotein 
AI, and a C-terminal repeat domain that binds 
fibronectin and fibrinogen. The capacity of SOF to 
opacify serum by disrupting the structure of high 
density lipoproteins may preclude its use as a 
vaccine antigen in humans. This study generated 
mutant forms of recombinant SOF with reduced 
(100-fold) or abrogated opacity factor (OF) activity, 
for use as vaccine antigens. However, the structural 
alterations introduced into the N-terminal SOF 
peptide (SOFΔFn) by mutagenesis to abrogate OF 
activity, abolish the capacity of SOF to protect 
against lethal systemic S. pyogenes challenge in a 
murine model. Mutant forms of purified SOFΔFn 
peptide were also used to assess the contribution of 
OF activity to the pathogenic processes of cell 
adhesion and cell invasion. Using latex beads coated 
with full-length SOF, SOFΔFn peptide or a peptide 
encompassing the C-terminal repeats (FnBD), we 
demonstrate that adhesion to HEp-2 cells is 
mediated by both SOFΔFn and FnBD. The HEp-2 
cell binding displayed by the N-terminal SOFΔFn 
peptide is independent of OF activity. We 
demonstrate that while the N-terminus of SOF does 
not directly mediate intracellular uptake by 
epithelial cells, this domain enhances epithelial cell 
uptake mediated by full-length SOF, in comparison 
to the FnBD alone. 
 
INTRODUCTION 
Streptococcus pyogenes (group A streptococcus; 
GAS4) is an important human pathogen 
responsible for a wide variety of skin and 
mucosal infections ranging from pharyngitis and 
impetigo to more severe invasive infections, such 
as necrotizing fasciitis and streptococcal toxic 
shock-like syndrome (1-3). The serum opacity 
factor (SOF) is a large protein of ~110 kDa which 
is expressed at the cell surface by approximately 
half of all clinical isolates (4,5). Similar to a 
number of other surface proteins expressed by S. 
pyogenes, SOF binds fibronectin via a C-terminal 
repeated domain (FnBD) (6-8), a function that 
has been implicated in the adhesion of GAS to 
epithelial cells (9). In contrast to the conserved C-
terminus, the N-terminus of SOF (SOFΔFn) is 
highly variable exhibiting ~55% identity between 
different serotypes of S. pyogenes. The N-
terminal domain of SOF was originally thought to 
cleave apolipoprotein A1 (apoAI) in human 
serum leading to the precipitation of high-density 
lipoproteins (HDLs) (10,11). However, it has 
recently been demonstrated that the OF activity of 
SOF is not enzymatic; rather, the direct binding 
of apoAI by SOF triggers the release of the HDL 
lipid cargo of apoAI, initiating the opacity 
reaction (12). This OF domain of SOF promotes 
GAS invasion of epithelial cells (13), but it is not 
known whether the OF activity itself or a discrete 
domain within the N-terminus of SOF contributes 
to this phenotype. SOF is a virulence determinant  
of GAS, with insertional inactivation or allelic 
replacement of sof reducing mortality in an 
intraperitoneal and subcutaneous murine infection 
model (13,14). SOF is also a vaccine candidate - 
parenteral immunization of mice with SOF 
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protects against lethal intraperitoneal challenge (15).  
 
It is not known what physiological effect that the 
precipitation of HDL would have upon the human 
host or how the interaction of SOF with apoAI 
contributes to the pathogenesis of GAS. ApoAI 
exerts a potent anti-inflammatory effect by 
preventing contact between infected T-cells and 
monocytes thereby inhibiting cytokine production 
(namely TNF-alpha and IL-1) in monocytes (16). In 
vitro, both HDL and apoAI exert anti-inflammatory 
effects against the potent bacterial endotoxins, 
Gram-negative LPS and Gram-positive lipoteichoic 
acid, binding strongly to both endotoxins and 
inhibiting the production of TNF-α (17-19). In vivo, 
transgenic animal studies of the toxicity of LPS 
have shown that expression of human apoAI 
transgenes protected mice from a lethal dose of LPS 
(20). ApoAI also possesses specific anti-bacterial 
and anti-viral properties (21-23).  
 
The administration of active SOF protein as a 
vaccine when the downstream effects of disrupting 
HDL and its activity in vivo are unknown would not 
be recommended, as the most effective protection 
against GAS infection is delivered when the SOF 
protein is administered parenterally (15) and the 
localized depletion of HDL may reduce the body’s 
defense against other pathogens or may result in 
inflammation at the site of immunization. Thus, 
before SOF could be used as a potential vaccine 
antigen (alone or as part of a multivalent vaccine 
formulation) it would be prudent to eliminate the 
OF activity of the protein. To this end, this study 
generated mutant forms of recombinant SOF protein 
with attenuated or eliminated OF activity, for use as 
vaccine formulations. These mutant SOF proteins 
are also been used to further delineate OF activity 
and cell binding activity within the N-terminus of 
SOF.  
 
MATERIALS AND METHODS 
Site directed mutagenesis - A pQE30 based vector 
encoding a fusion protein of residues 33–872 of 
SOF from a M75 GAS strain (lacking signal 
sequence and fibronectin binding repeat region, 
pSOF75ΔFn) (24), was used as the template for all 
mutagenesis reactions. Site directed mutagenesis 
was performed as previously described (25). 
Primers for site directed mutagenesis are given in 
supplementary material Table 1. Two mutagenesis 
strategies were employed, amino acid residues 
were substituted with alanine (single residues up 
to 5 residues) and small deletions were made 
within rSOF75ΔFn. Deletions within rSOF75ΔFn 
were generated by using site directed mutagenesis 
to introduce two AvrII restriction sites flanking 
the region to be deleted, followed by digestion 
with AvrII. The digested fragments were then 
separated by agarose gel electrophoresis, and the 
DNA fragment containing the portion of 
pSOF75ΔFn of interest was extracted from the 
gel and re-ligated. 
 
Expression and purification of wildtype and 
mutant forms of rSOF75 and rSOF75ΔFn 
protein - Large-scale expression and purification 
of rSOF75 proteins was conducted essentially 
according to manufacturer’s instructions 
(Qiagen), and has been previously described 
(13,26). To ensure correct refolding of proteins 
was achieved, wildtype purified proteins were 
subsequently tested for opacity factor activity 
using an agarose overlay method (7). 
 
Structural characterisation of wildtype and 
mutant forms of rSOF75ΔFn protein - To 
determine the structural integrity of mutant 
rSOF75ΔFn proteins in comparison to the 
wildtype, a comparison of the secondary structure 
of wildtype and mutant rSOF75ΔFn proteins was 
conducted using circular dichroism (CD) 
spectroscopy. CD spectra were acquired using a 
Jasco J-810 Spectropolarimeter (Jasco). 
Experiments were conducted at room temperature 
with proteins at a concentration of approximately 
0.2 mg/ml in 10mM sodium phosphate buffer, pH 
7.5 containing 50% trifluoroethanol (27,28). Far 
UV spectra were recorded from 190-250 nm in a 
0.1 cm path length cell (Starna) containing 400 μl 
of protein solution. The data shown represents an 
average of ten scans, corrected for a buffer 
baseline. Mean residue ellipticity (MRE; [θ]) was 
calculated using the following formula (29): 
 
MRE [θ] =           θ x 100 x molecular weight                            
.                    conc (mg/ml) x path length x 1000 x 
no. of residues 
 
The α-helical content of wildtype and mutant 
forms of rSOF75ΔFn was calculated from the 
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MRE value at 222 nm using the following equation 
as described by (30). 
 
%α-Helix = MRE[θ]222 − 2340     × 100 
                               30300  
 
Opacity Activity Assays – Qualitative opacity factor 
assays were conducted using the serum agarose 
overlay method (7). The serum overlay method 
permits visual confirmation of OF activity, as 
binding of apoA1 by SOF causes precipitation of 
apoAI and HDL, which appears as an opaque white 
band on the solid serum/agarose medium. Data is 
presented as an inversion of the actual blot with 
opacity activity appearing as a dark band on a light 
background. Quantitative opacity factor assays were 
conducted using purified HDL or human serum 
using the method of Courtney et al. (12), with 
opacification measured as absorbance at 405nm. 
 
ApoAI binding capacity – Wells of a microtiter 
plate were coated with 20 μg/ml rSOF75 protein or 
gelatin in 0.01 M sodium bicarbonate for 1 h at 
37°C. Plates were washed with PBS and blocked 
with gelatin (1 mg/ml in PBS) for 1 h at 37°C, 100 
μl of biotinylated (Pierce) apoAI (Calbiochem) was 
added and incubated at 37°C for 1 h. Following 
washing 100 μl of avidin-peroxidase (0.5 μg/ml) 
was added to the wells and incubated at 37°C for 1 
h. the plates were washed and 3.3’, 5.5’-
tetramethylbenzidine substrate added. Colour 
development was stopped using 1 M phosphoric 
acid and the absorbance at 650nm was recorded. 
Binding was assayed in triplicate, binding to gelatin 
was considered non-specific and was subtracted 
from the readings. 
 
Interaction of SOF coated latex beads with HEp-2 
cells - Assays of the interaction of SOF coated latex 
beads with HEp-2 cells were conducted as per 
previously published methods (13,31,32). 
Preliminary assays were conducted in DMEM 
HEPES supplemented with either 10% FCS or 1% 
FCS. However, differential binding was observed 
between these two assay conditions, the rSOF75ΔFn 
only mediated binding to HEp-2 cells when 
incubated in DMEM HEPES 1% FCS, and thus 
these conditions were used for all further latex bead 
adherence assays. The efficiency of protein loading 
on to latex beads was measured by FLUOstar 
fluorescent plate reader (BMG Labtech) using 
anti-SOF75 rabbit serum and fluorescent labeling 
with goat anti-rabbit Alexa 488 (green) 
(Molecular Probes) (data not shown), protein 
loading efficiency was found to be comparable 
for all protein domains. To determine the effect of 
exogenous addition of the rFNBD domain on the 
adhesion and internalization of rSOFΔFn coated 
latex beads, purified rFnBD at 1, 5 or 10 μg/ml 
was pre-incubated with the HEp-2 cells for 1 h 
prior to addition of the coated latex beads, and 
was maintained throughout the subsequent 4 h 
incubation with the latex beads. 
 
 
Confocal microscopy studies - HEp-2 cells (after 
incubation with the coated latex beads) were 
fixed for 30 min on ice in 500 μl/well of pre-
chilled 4% paraformaldehyde in PBS, and then 
washed twice in PBS. Cells were then blocked by 
the addition of 200 μl/well of PBS containing 
10% foetal calf serum and incubated for 30 min at 
room temperature. The blocking solution was 
then removed and the cells were incubated with 
either protein-G purified rabbit polyclonal anti-
SOF75 antibodies (26) (30 μg) or rabbit 
polyclonal anti-FnBD antibodies (1:100 dilution)  
for 45 min at room temperature. Following 
washing with PBS, cells were incubated with goat 
anti-rabbit Alexa 488 diluted 1:400 in PBS 
containing 10% BSA (Molecular Probes) for 1 h 
at room temperature and subsequently washed 
with PBS. Cells were permeabilized with 200 
μl/well of 0.1% (v/v) triton X-100 in PBS for 30 
min on ice, washed in PBS, followed by storage 
at 4°C overnight. The following day, cells were 
treated with goat anti-rabbit Alexa 633  diluted 
1:400 in PBS containing 10% BSA (Molecular 
Probes) for 1 h and washed three times in PBS. 
Cells were then mounted onto a glass slide using 
Mowiol solution (Calbiochem). Images were 
recorded using a Leica TCS SP confocal 
microscope mounted on a Leica DM IRBE 
inverted microscope  with Leica TCS NT 
software (Version 2.61; Leica Microsystems). 
 
Mouse immunization and challenge - To 
determine the protective efficacy of rSOF75ΔFn 
proteins challenge studies were performed. 
BALB/c mice (n=10) were immunized 
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subcutaneously with 25 µg of wildtype or mutant 
forms of rSOF75ΔFn protein in incomplete Freunds 
adjuvant. Control mice received a subcutaneous 
injection of PBS. After 2 weeks, the mice were 
boosted with an intramuscular injection of another 
25 µg of each protein in PBS. Control mice received 
a PBS injection. Two weeks after the booster 
injections, all mice were challenged by an 
intraperitoneal injection of ~1 x 109 CFU of the 
SOF-positive M49 GAS strain 591 (33). The 
number of surviving mice was recorded daily. 
Moribund mice were sacrificed and recorded as 
dead. 
 
Serum samples were collected on days 0 and 28, 
and stored at –20°C prior to determination of 
rSOF75ΔFn-specific antibodies. In brief, 96-well 
Nunc-Immuno MaxiSorp assay plates (Nunc) were 
coated with 2 µg/ml of wildtype rSOF75ΔFn in 
coating buffer (bicarbonate, pH 9.4). After 
overnight incubation at 4°C, plates were blocked 
with 1% BSA in PBS (pH 7.4) for 1 h at 37°C. 
Serial 2-fold dilutions of serum in PBS with 1% 
BSA were added (100 µl/well), and plates were 
incubated for 1 h at 37°C. After four washes, 
secondary biotinylated antibodies were added 
followed by 1 h incubation at 37°C. After six 
washes, 50 µl/well of peroxidase-conjugated 
streptavidin (Pharmingen), diluted 1:1000, was 
added and plates were further incubated for 45 min 
at room temperature. After a final six washes,  
the substrate ABTS (2,2´-azino-bis(3-
ethylbenzthiazoline-6-sulfonic acid)) in 0.1 M 
citrate-phosphate buffer containing 0.1% H2O2 was 
added, and plates were incubated for 30-60 min at 
room temperature. The absorbance was measured at 
a wavelength of 405 nm. 
 
Statistical Analyses - For apoAI binding 
experiments, an unpaired t-test was used to 
determine if there was any significant difference in 
the apoAI binding ability of wildtype and mutant 
SOF proteins. For latex bead experiments, a one 
way ANOVA using Bartlett’s test for equal variance 
was used to determine whether there was any 
significant variation in the median number of beads 
attached to or taken up by HEp-2 cells, followed by 
a Tukey's Multiple Comparison Test for individual 
comparison of adherence and internalisation 
mediated by two different proteins. For 
immunization and challenge experiments, a 
Kruskal-Wallis test was used to determine 
whether there was any significant variation in the 
median titers of the four groups of antisera. 
Dunn’s Multiple Comparison test was used for 
individual comparison of two groups of antisera. 
Difference in survival curves was determined by 
log rank test. All statistics were performed using 
GraphPad Prism version 4.02 (Graph-Pad 
Software Inc., San Diego, CA, USA).  
 
RESULTS 
SOF is a unique multi-functional protein, capable 
of binding fibronectin via a C-terminal domain 
designated FnBD (8,24) and apoAI via an N-
terminal domain (12) (Fig. 1A). The N-terminal 
domain of SOF (SOFΔFn) has been shown to 
mediate adhesion to HEp-2 cells and promote 
HEp-2 cell invasion by whole GAS cells . In 
order to assess the contribution of the OF activity 
of SOF in the processes of HEp-2 epithelial cell 
adhesion and invasion, deletion mutagenesis was 
used to eliminate the OF activity of recombinant 
rSOF75ΔFn. Deletion was undertaken to remove 
between 22 and 63 amino acid residues of the 
rSOF75ΔFn protein (between P148 and K211; P210 
and E232; K231 and D286; V285 and E315).  Each of 
the rSOF75ΔFn deletion mutants lacked OF 
activity (Fig. 1B). The 
rSOF75ΔFnDEL[P210 E232] mutant was also 
found to lack OF activity when incubated in 
human serum or human HDL (Fig. 2). In order to 
delineate specific amino acid residues that 
contribute to OF activity, site directed 
mutagenesis to alanine was undertaken on 52 
amino acids of SOF75ΔFn that are 100% 
conserved in 16 different SOF sequences 
(Supplementary Fig. 1 and Supplementary Table 
1). A mutant form of rSOF75ΔFn with attenuated 
OF activity (100 fold reduction in activity) was 
constructed by simultaneously substituting 5 
amino acids with alanine (D218; S226; K228; M229; 
E232) (Fig. 1C). The rSOF75ΔFn[D218A-S226A-K228A-
M229A-E232A] protein has attenuated OF activity 
when incubated with either human serum or 
human HDL (Fig. 2). In order to determine if the 
loss or attenuation of OF activity was due to a 
decrease in the apoAI binding capacity of SOF, 
the ability of rSOF75ΔFnWT, rSOF75ΔFn[D218A-
S226A-K228A-M229A-E232A] and 
rSOF75ΔFnDEL[P210 E232] to bind biotinylated 
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apoAI was assayed (Fig. 2D). There was no 
significant decrease in apoAI binding by the mutant 
proteins, suggesting that the loss of OF activity 
occurs via an alternative mechanism. 
 
The impact of the mutations to rSOF75ΔFn on 
protein structure was analyzed using far- 
UV CD spectroscopy. rSOF75ΔFnWT had a CD 
emission spectrum typical of proteins containing 
both α helices and β sheets, with a characteristic 
minimum at ~220 nm, a second larger minimum at 
~207 nm and a maximum at 190 nm (34). Of the 
rSOF75ΔFnDEL mutant proteins generated, 
rSOF75ΔFnDEL[K231 D286] could not be purified 
for structural analysis. Far-UV CD spectra obtained 
for rSOF75ΔFnDEL[P148 K211], rSOF75ΔFnDEL 
[P210 E232] and rSOF75ΔFnDEL[V285 D315] 
indicate perturbation to the secondary structure of 
the proteins. The rSOF75ΔFnWT is predicted to 
contain 27% alpha helicity, with a predicted 24% 
alpha helical content in rSOF75ΔFnDEL 
[P148 K211], 21% in rSOF75ΔFnDEL 
[P210 E232] and 22% in rSOF75ΔFnDEL 
[V285 D315]. A concomitant shift towards a more 
disordered structure was observed for each deletion 
mutant, as indicated by a shift in the 207 nm 
minima to a shorter wavelength of 204 nm for 
rSOF75ΔFnDEL[P148 K211] and rSOF75ΔFnDEL 
[P210 E232] and 205.5 nm for rSOF75ΔFnDEL 
[V285 D315] (Fig. 3) (34,35). In contrast to the 
loss of secondary structural elements in the 
rSOF75ΔFnDEL mutants, the rSOF75ΔFn[D218A-S226A-
K228A-M229A-E232A]
 mutant had increased secondary 
structure when compared to rSOF75ΔFnWT, with an 
increase in predicted alpha helicity from 27% to 
29% (Fig. 3).  
 
In order to assess the direct contribution of the OF 
activity of SOF in the processes of HEp-2 epithelial 
cell adhesion and invasion, the ability of latex beads 
coated with wildtype OF-positive, mutant OF-
negative and OF-attenuated forms of the 
rSOF75ΔFn protein to bind to the human 
pharyngeal epithelial cell line HEp-2 was assayed. 
These studies indicate that the SOFΔFn domain 
mediates attachment to HEp-2 cells, with the latex 
beads coated with rSOF75ΔFnWT adhering to HEp-2 
cells in numbers equivalent to latex beads coated 
with the full length rSOF75 (p>0.05), and 
significantly more latex beads coated with 
rSOF75ΔFnWT adhering to HEp-2 cells than latex 
beads coated with a protein encompassing only 
the fibronectin binding domain of the SOF 
protein (rFNBD) (p<0.01). Furthermore, this 
HEp-2 adherence mediated by the SOFΔFn 
domain is not dependant on OF activity, with 
latex beads coated with rSOF75ΔFn[D218A-S226A-
K228A-M229A-E232A]
 (attenuated OF activity) and 
rSOF75ΔFnDEL[P148 K211] (abolished OF 
activity) mediating adherence at the same level as 
the rSOF75ΔFnWT protein (p>0.05) (Fig. 4A, C). 
Latex beads coated with rSOF75ΔFnDEL 
[P210 E232] and rSOF75ΔFnDEL[V285 D315] 
have a significantly reduced capacity to attach to 
HEp-2 cells when compared to rSOF75ΔFnWT 
(p<0.01), however, there were significantly more 
latex beads coated with rSOF75ΔFnDEL mutants 
attached to HEp-2 cells than were observed with 
the BSA control (p<0.01). It has been previously 
demonstrated that the SOFΔFn domain of SOF 
possesses pro-invasive properties when expressed 
on the surface of non-invasive GAS strains or 
non-invasive Lactococcus lactis (13). However, 
while the SOFΔFn promotes epithelial cell 
invasion in these backgrounds, this study has 
shown that the SOFΔFn protein domain is not 
sufficient per se to mediate intracellular invasion 
of HEp-2 cells (Fig. 4B, C). However, while it is 
apparent that the N-terminus of SOF does not 
directly mediate epithelial cell invasion, it may be 
concluded that this domain enhances the 
epithelial cell invasion by full-length SOF, in 
comparison to the FnBD alone. A significantly 
greater proportion of latex beads coated with 
rSOF75 were found to be intracellular (57.1%) 
than latex beads coated with FnBD alone (31.8% 
intracellular) (p<0.01) (Fig. 4B).  
 
While SOF is a protective antigen in murine 
vaccination studies, the capacity of SOF to 
opacify serum raises questions about its use in 
humans. The capacity to knock-out OF activity 
while retaining the structural and functional 
integrity of the molecule may be a requirement 
for further evaluation of SOF as a human vaccine 
candidate. To this end, the protective efficacy of 
rSOF75ΔFnWT, rSOF75ΔFn[D218A-S226A-K228A-M229A-
E232A] and the corresponding deletion mutant 
rSOF75ΔFnDEL[P210 E232] were assessed in a 
murine model of lethal GAS challenge. 
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rSOF75ΔFnWT, rSOF75ΔFn[D218A-S226A-K228A-M229A-
E232A] and rSOF75ΔFnDEL[P210 E232] all elicited 
significantly elevated titres of anti-rSOF75ΔFnWT 
serum IgG (p<0.001; p<0.01, p<0.01) (Fig. 5A). In 
concordance with the results of Courtney et al. (15), 
mice immunized with rSOF75ΔFnWT showed 
significantly increased survival when challenged 
with the SOF-positive M49 GAS strain 591 
compared with PBS control mice (p = 0.0069). 
While mice immunized with rSOF75ΔFn[D218A-S226A-
K228A-M229A-E232A], and the corresponding deletion 
mutant rSOF75ΔFnDEL[P210 E232] showed 
increased survival when compared to the control 
mice, this increase was not statistically significant 
(p>0.05) (Fig. 5B). While Courtney et al. (15) have 
previously shown that parenteral immunization with 
rSOF2ΔFn protects against lethal systemic 
challenge with an M2 GAS strain, this is the first 
study to show that immunization with SOF can 
protect against lethal challenge with a heterologous 
GAS strain.  
 
DISCUSSION 
SOF is a unique multifunctional protein which may 
contribute to GAS pathogenesis by virtue of its 
abilities to interact with a variety of components of 
plasma and the extracellular matrix.  A number of 
GAS surface proteins have a role in promoting host 
epithelial cell invasion including SfbI (36,37), M 
protein (31,38,39), PrtF2 (40,41), FbaA (42) and 
SOF (13). M protein and SfbI mediate intracellular 
invasion via two distinct pathways, both of which 
are dependant on fibronectin binding. M protein-
mediated ingestion of GAS depends on co-
engagement of the CD46 receptor and fibronectin 
via separate domains of the M protein; fibronectin 
in turn acts as a bridging molecule binding α5β1 
receptors at the host epithelial cell surface. (43-46). 
The formation of the M protein-fibronectin-α5β1 
complex and engagement of the CD46 receptor 
results in intracellular signaling cascades that lead 
to cytoskeletal rearrangement for ingestion of the 
bacteria (31,47). As opposed to M protein, SfbI 
requires only an interaction with fibronectin to 
trigger intracellular invasion, since the two 
fibronectin binding domains on SfbI co-operatively 
bind fibronectin which in turn binds α5β1 integrins 
on the host cell surface (44,45). The resultant  
complex triggers the formation and recruitment of 
caveosomes which may allow GAS to persist within 
host cells without exposure to the acidic 
environment of phagosomes or lysosomes (48). 
While it has been clearly demonstrated through 
specific gene deletion that SOF, PrtF2 and FbaA 
are mediators of intracellular invasion of 
epithelial cells, the mechanism via which these 
surface protein mediate internalisation is not 
known. The work of Timmer et al. (13), using 
SOFΔFn expressed at the surface of SOF-
negative GAS and the heterologous species L. 
lactis, found that the N-terminal OF domain of 
SOF contributes to epithelial cell invasion 
independently of the C-terminal fibronectin 
binding domain. However, using latex beads 
coated with SOF protein, we demonstrate that the 
N-terminal OF domain is not intrinsically 
sufficient to mediate epithelial cell invasion, but 
will significantly enhance intracellular invasion in 
the presence of FnBD. Different GAS strains 
express a wide array of surface anchored proteins 
that interact with fibronectin, the M49 GAS strain 
used in the experiments of Timmer et al. (13) 
expresses both FBP54 and PrtF2 (40,49). Thus, in 
this case the SOFΔFn expressed on the surface of 
M49 GAS may enhance cellular uptake, as the 
requirement for fibronectin binding may be 
achieved by FBP54 and PrtF2 expressed at the 
surface of the M49 GAS cells. However, the 
exogenous addition of rFnBD does not induce 
internalisation of rSOFΔFn (results not shown), 
suggesting that fibronectin binding must be 
coupled at the surface of the latex bead or GAS 
cell for enhanced internalisation to occur.  
 
Incubation of cells with exogenous rSOFΔFn 
does not enhance uptake of GAS cells but inhibits 
internalisation in a concentration dependant 
manner (13), suggesting that the interaction of the 
N-terminal domain of SOF with the epithelial cell 
surface occurs via a specific receptor on the 
surface of HEp-2 cells. 
 
We have previously demonstrated (13) that the N-
terminal OF domain of SOF mediates tight 
adherence to epithelial cells. Thus, SOFΔFn 
mediated adherence to the surface of epithelial 
cells most likely occurs via a mechanism 
independent of that required for the opacity 
reaction.  The finding that these mutations clearly 
diminished the ability of SOF to opacify HDL but 
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did not alter its binding to apoA1 indicated that 
other functions of SOF related to the opacity 
reaction were altered.  Recent data suggest that SOF 
is a heterodivalent fusogenic protein that opacifies 
HDL by binding and crosslinking HDL particles 
resulting in the displacement of apoA1, fusion of 
the HDL particles, and the extrusion of a delipidated 
HDL particle (50). This mechanism produces a very 
large lipid particle that is enriched in cholesterol 
esters and essentially depleted of apolipoproteins.  
Thus, we propose that the described mutations of 
SOF alter the opacity reaction by interfering with 
one or more of these processes. The expression of 
multifunctional proteins at the surface of GAS is a 
common theme. For instance, M protein, SfbI, and 
the hyaluronic acid capsule each have dual 
functions in epithelial cell interactions and 
phagocytosis resistance (31,36-39,51-54), while 
glyceraldehyde-3-phosphate dehydrogenase 
functions as a glycolytic enzyme and binds multiple 
serum proteins including plasmin and fibronectin 
(55,56). SOF joins an increasing list of 
multifunctional surface proteins of GAS. 
 
As an immunogenic surface protein of GAS, SOF is 
a candidate vaccine antigen. While SOF was shown 
to lack protective efficacy against mucosal 
challenge when administered intranasally (57), SOF 
is a promising vaccine against systemic infection as 
parenteral immunization of mice with SOF2ΔFn 
protects against lethal intraperitoneal challenge (15). 
Unlike in Europe and the United States, where the 
throat is often the primary tissue reservoir, the skin 
is the major site of infection among a number of 
populations in which GAS infection is endemic 
including the Australian aboriginal population (58), 
populations of India and Trinidad, American 
Indians and Polynesians living in New Zealand (59-
61). Thus, there is a need for protective antigens for 
use in areas such as the tropical north of Australia, 
where the skin is the primary route of GAS entry. 
Two of the prime vaccine candidates from the 
surface proteome of GAS, SfbI and the conserved 
C-terminal epitopes of M protein, while effective at 
eliciting protection against mucosal colonization, 
have proven ineffectual at reducing the rate of 
mortality due to systemic GAS infection in murine 
models (62,63). While SOF has proven to be 
protective against systemic infection, it is not 
known what physiological effect the interactions 
between HDL and SOF would have upon the human 
host following vaccination. It would be prudent to 
eliminate the OF activity of the SOF protein to 
ensure undesirable side effects do not occur. To 
this end the OF attenuated (rSOF75ΔFn[D218A-
S226A-K228A-M229A-E232A]) and corresponding OF 
negative (rSOF75ΔFnDEL[P210 E232]) mutants 
generated in this study were examined to 
determine the protective efficacy of the mutants 
against lethal systemic GAS infection. 
Unfortunately, while the mutant proteins 
remained immunogenic, the structural alterations 
introduced upon mutagenesis may have prevented 
accessibility of protective epitopes or altered the 
protective epitopes such that mice immunized 
with rSOF75ΔFn[D218A-S226A-K228A-M229A-E232A] or 
rSOF75ΔFnDEL were not significantly protected. 
Other protective epitopes in streptococcal 
antigens including the M protein of GAS  and the 
Group B streptococcus polysaccharide capsule 
and alpha C protein (64,65), are conformational 
in nature and as such will only be protective if 
presented to the host immune system in their 
native conformation. In addition, maintenance of 
the conformational structure may enhance the 
immune response to epitopes of M proteins of 
GAS (66). The protective efficacy of the main 
protective epitope of SOF may have been altered 
by a loss of conformation associated with 
mutagenesis performed in this study. This study 
has shown that SOF can protect against 
intraperitoneal challenge by a heterologous GAS 
strain. This data in conjunction with previous 
findings that antiserum against one serotype of 
GAS was bactericidal for multiple GAS serotypes 
(15) suggests that SOF contains common 
protective epitopes. 
 
The SOF protein is a virulence determinant in 
GAS with affinity for multiple serum proteins 
including fibrinogen (67), fibronectin (8,24) and 
apoAI (12). Additionally, SOF plays a role in 
epithelial cell adhesion and invasion (9,13) and 
phagocytosis resistance (68).This study has 
shown that the N-terminus of SOF mediates 
binding to HEp-2 cells and delineates this binding 
activity from the ability of the N-terminus of SOF 
to opacify serum. This study is the first to 
indicate that vaccination with SOF can protect 
against infection by a heterologous GAS serotype 
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FIGURE 1: The domain structure, opacity factor activity and adherence phenotypes of 
SOF, rSOF75, rSOF75ΔFnWT, and the rSOF75ΔFn mutants generated in this study. A, 
Schematic representation of the SOF75 protein. SS, signal sequence; FnBD, fibronectin binding 
domain; MSD, membrane spanning domain. The domain mediating opacity factor (OF) activity is 
indicated by a bracket. Boxes represent the domains encompassed by the rSOF75 proteins used in 
this study. B, Opacity factor phenotype of wildtype and mutant forms of the rSOF75ΔFn peptide 
as indicated by the serum agarose overlay method.  
 
FIGURE 2: The OF activity and apoAI binding capacity of wildtype and mutant forms of 
rSOF75ΔFn. A, OF activity over 24 h was determined by adding 1 μg/ml of either 
rSOF75ΔFnBDWT, rSOF75ΔFn[D218A-S226A-K228A-M229A-E232A] or rSOF75ΔFnDEL[P210 E232] to 
human serum and recording the A405nm at timed intervals. B, C, the opacification of serum (B) 
or HDL (C) as a function of protein concentration. Human serum or purified human HDL was 
treated with the indicated concentration of protein for 24 h and the absorbance determined at 405 
nm. D, binding of biotinylated apoAI by either rSOF75ΔFnBDWT, rSOF75ΔFn[D218A-S226A-K228A-
M229A-E232A] or rSOF75ΔFnDEL[P210 E232]. 
 
FIGURE 3: rSOF75ΔFn mutants have perturbed secondary structure. The spectra of 
wildtype rSOF75ΔFn (solid line) compared to mutant forms of recombinant SOF75ΔFn (dotted 
line). A, rSOF75ΔFnDEL[P148 K211]; B, rSOF75ΔFnDEL[P210 E232]; C, rSOF75ΔFnDEL 
[V285 D315]; D, rSOF75ΔFn[D218A-S226A-K228A-M229A-E232A]. All proteins exhibit CD emission 
spectra characteristic of proteins containing both α helices and β sheets, displaying a 
characteristic minimum at ~220 nm, a second minimum at ~207 nm and a maximum at 190 nm. 
CD spectra in A, B and C show a shift in the latter minimum to a shorter wavelength indicating an 
increase in the proportion of the protein having disordered structure. 
 
FIGURE 4: SOFΔFn promotes association of latex beads to HEp-2 cells independent of OF 
activity A, The total number of SOF coated latex beads per 10 HEp-2 cells. SOF coated latex 
beads were incubated with HEp-2 cells for 4 hours in DMEM HEPES supplemented with 1% 
FCS. Asterisks indicate adherence significantly lower than that mediated by the recombinant full 
length SOF, rSOF75 (p<0.001) B, C, Binding and uptake of SOF-coated latex beads by HEp-2 
cells. Following incubation with latex beads, internal and external beads were differentiated using 
double immunofluorescence confocal microscopy. External beads were labeled by incubation 
with SOF specific rabbit anti-serum, followed by goat anti-rabbit Alexa-488 conjugated antibody 
(green). Internal beads were labelled by subsequently permeabilizing the cells using 0.1% Triton 
X-100, and subsequently incubating the cells with SOF-specific rabbit antiserum, followed by 
goat anti-rabbit Alexa-633 conjugated antibody (red). C, A sample of images obtained using 
double immunofluorescence microscopy. Binding and uptake mediated by rSOF75, rFnBD and 
rSOF75ΔFn peptides is shown. Binding mediated by SOF75ΔFn[D218A-S226A-K228A-M229A-E232A] with 
attenuated OF activity and rSOF75ΔFnDEL[P148 K211] with abrogated OF activity is also 
shown. 
 
FIGURE 5: The murine response to parenteral immunization with wildtype and mutant 
forms of rSOF75ΔFn and subsequent lethal intraperitoneal challenge A, Antibody titres 
directed against rSOF75ΔFnWT 28 days post intravenous immunisation with either 
rSOF75DFnWT, rSOF75ΔFn [D218A-S226A-K228A-M229A-E232A] or rSOF75ΔFnDEL[P210 E232]. Bars 
represent specific IgG present in the serum of control and vaccinated mice, with results expressed 
as geometric means, error bars represent standard error of the mean (n=10). Asterisks indicate 
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titres significantly greater than the control. B, Survival of intravenously immunized mice after 
lethal challenge with a heterologous S. pyogenes strain. Mice (n=10) vaccinated with either 
rSOF75ΔFnWT, rSOF75ΔFn[D218A-S226A-K228A-M229A-E232A] or rSOF75ΔFnDEL[P210 E232] were 
challenged with ~1x109 CFU of virulent M49 S. pyogenes strain 591. Mortality was recorded 
daily. Significance was determined using the log rank test. 
 
SUPPLEMENTARY FIGURE 1: ClustalW alignment of the amino acid sequence of the N-
terminal domain of SOF from 16 different GAS strains. 100% conserved amino acid residue 




























































































































































































































































































































































































































































































SOF90  33 ST----STETSTAS-----------ASA   45 
SOF90      33 ST----STETSTAS-----------ASA   45 
SOF13   33 ST-GASSTETS--------------AST   45 
sof75                33 NA----STETSASS-----------TTS   45 
sof22               33 NA----STETSASS-----------TTS   45 
SOF4        33 S--TTGSTETS--------------AAS   44 
SOF4      33 S--TTGSTETS--------------AAS   44 
sof2                33 SA-STTSTETS-----------------   42 
SOF4.2      33 TA----NTETSTTP-----------ATT   45 
sof28               33 SA-S-SSTESST-------------TTA   45 
SOF11      33 S--TTGSTETS--------------AAS   44 
SOF22      33 SA-NTTSTETSTPSTTE-TSVSASAGTS   58 
SOFSTNS554   33 SA-STTSTETS----------AASAGTT   49 
SOF76      33 STGASSSTETS----------ASSNNTN   50 
sof63               33 ST--TGSTETS----------AASTTTS   48 
sof49               33 ST-GVSNTEASASSTNTNTASADATASG   59 
SOF100      33 ST-GATSTESSTTSTAS-------ASTD   52 
 
SOF90      46 GATTNETTATIPSASTGTGEAAGSGTGSEAN--------GASSVVSSEESQSSESAPASP   97 
SOF90      46 GATTNETTATIPSASTGTGEAAGSGTGSEAN--------GASSVVSSEESQSSESAPASP   97 
SOF13         46 NTST-------ASAGTSTSETAASGTGSEA------------AVVSSEGSQSSESAPASP   86 
sof75               46 TASTAET----STP-TGTSGTAASGASGEAT--------VATANGGPQSAPATSEATPQP   92 
sof22               46 TASTAET----STP-TGTSGTAASGASGEAT--------VATANGGPQSAPATSEATPQP   92 
SOF4     45 TASTAETS-----TTTGTNGTAASGASGESS---------DVSVTSSGGSQSSESAPASP   90 
SOF4      45 TASTAETS-----TTTGTNGTAASGASGESS---------DVSVTSSGGSQSSESAPASP   90 
sof2                43 TASAGVGT-----SGTAASET-GSGAAVTTAT-----TTTATTNGGPQSTPAVAEAT--P   89 
SOF4.2      46 TPSAGTGT-----ATTSGTATTTPSATTDAGGEAGSGTNGASSVTSSGGSQSSGTTPASP  100 
sof28               46 NTGTGTAS-----GMTATTPSATTDTGEAAGSGARSEANGASSVVSSEESQSSGTTPASP  100 
SOF11      45 TASVDATT----------SGTTANGASGESS---------DASVASSEGSQSSKSAPASP   85 
SOF22      59 TSGTVATTPS---ASTGTDGAAGSGTNGASS------------VTSSGGSQSSESAQTLP  103 
SOFSTNS554      50 ASGTTATA---PSATTGTGEAAGSGTNGASS------------VTSNGGSQSSESAQAST   94 
SOF76      51 TASTVETS-----TTTSTSGTAASGTGSEAA------------VVSSEGSQSSESAQASP   93 
sof63               49 TASTVETS-----TTTGTSVTAASEASSESSD-------V--SVVSSEGSQSSASAPASP   94 
sof49               60 TAATT------PSAGTSTSTGEAAGSGLSSEANW-----SDAAVASSGGSQSSGTTPASP  108 
SOF100        53 TATTSGAAT----TTTGTSGTAASGTASGTNG--------ASSVTSSGGSQGSESAQASP  100 
 
SOF90      98 ------QAHTASAATSTS-------------SASSSNE-K---TLKTATTSTSTSSTPVA  134 
SOF90      98 ------QAQTASAATSTS-------------SASSSNE-K---TLKTATTSTSTSSTPVA  134 
SOF13         87 ------QAQTASAATSTS-------------SASSSNE-K---TLKTATTSTSTSSTPVA  123 
sof75               93 ------QAQAAPAASAPT-------------TVTSSSS-SDSDAKTPKAASTTSSSATVA  132 
sof22               93 ------QAQAAPAASAPT-------------TVTSSSS-SDSDAKTPKAASTTSSSATVA  132 
SOF4       91 QP----QAQTATVAATSA-------------SSTSSSS-EEQAPKAV--TSSTPPSTPVA  130 
SOF4      91 QP----QAQTATVAATSA-------------SSTSSSS-EEQAPKAV--TSSTPPSTPVA  130 
sof2                90 QP----QAQIAPVAAATS-----------TSSASSSSDGKAPQAV----TSSTSPSTPAA  130 
SOF4.2        101 QP----QAQTTPAATSIS-------------SNSSS---DGQIPK----TAITSPSTPVA  136 
sof28               101 ------QAQTAPAATSTS-------------SVSSS---NEKTPKT---ATTTTSSTPVA  135 
SOF11      86 QPQPQPQAQTAPAATSAS-------------SKAKT---EEQTPKAATSSTPSTPSTPAA  129 
SOF22        104 ------QAQTATVASAST------------IASPSSSSASASDVKAPRAATSSTPSTPAA  145 
SOFSTNS554      95 ----QPQTQTATATSS--------------SSSNTNGPSSSSEEKTPKTATSSTSSTSST  136 
SOF76      94 ------QAQTAPVAATSA------------SSTSSSSEAN-SDVKAPQAASTTSASSTPA  134 
sof63               95 ----QPQAQTPPAATS--------------TSSASSSSSE--D-KASKAATSSTSSSTPA  133 
sof49              109 ------QAQTAPAATTTT------------------SSASSSNEKPLKTATTTTSSTPAA  144 
SOF100        101 ------QAQTAPVAAEATPKPQAQTGVASPSNLSNTNGSSSSETQTFKSAGTTTSSAPAA  154 
 
SOF90     135 STSNN---SNKVTSTEAETPMMDVEQYTVDKKDSSVTQTDDK-----------KLLKIRR  180 
SOF90     135 STSNN---SNKVTSTEAETPMMDVEQYTVDKKDSSVTQTDDK-----------KLLKIRR  180 
SOF13      124 STSNN---SNKVTSTEAETPMMDVEQYTVDKKDSSVTQTDDK-----------KLLKIRR  169 
sof75              133 SPSNG---SNKEANAETAPQMMDVEQYKIKDENSSITVADKA-----------KQLKIRR  178 
sof22              133 SPSNG---SNKEANAETAPQMMDVEQYKIKDENSSITVADKA-----------KQLKIRR  178 
SOF4      131 ASTSS--NSNQVTGTEASPQMMDVERYTVDKESSELKVKDGKNPKNGSKVN--KDTKLIR  186 
SOF4     131 ASTSS--NSNQVTGTEASPQMMDVERYTVDKESSELKVKDGKNPKNGSKVN--KDTKLIR  186 
sof2               131 ASSNG---SNQEASAETEPQTMEVEKYTVDKENSKLNIKDGKTPKTGSSVNNEKDTKLIR  187 
SOF4.2     137 ASNN----SNQEASAETEPQTMEVEKYTVDKEN-QAKYKDGDKPKNGSSVD-DKDTKLIR  190 
sof28              136 STSNN---SNKVTSTEAETQTVDVERYTVDKENSKLNIKDGKTPKTRSSVN--KDTKLIR  190 
SOF11     130 SSSSN---SNQEASAETEPQMMDVEKYTVDKESSELKVKDGKKPKNENKVD--KDTKLIR  184 
SOF22     146 STSS--N-SNQVTGTEASPQMMDVEQYTIDKKETELKVKDGKE-TNGSGVN--KKLIRNR  199 
SOFSTNS554    137 PAAASNN-SNQEASTEVETPMMEVEQYTVDKEKTELTVKDGNK-LNSSGSD--K--QLIN  190 
SOF76     135 AASN--N-SNKVTGTEVEPQMMDVEQYKVNKEKTELTVKDGTQPKNGRTVNQNKNIKLIR  191 
sof63              134 VASSSSN-SNQATGTEVEPQMMEVEQYTVNKESSELKVKDGKE-MNGSGVS--K--KLIR  187 
sof49              145 SSSS--N-GNQVTGTEVEPQMMDVEQYKVDKENSELTVKVDRR-----------QLKIRK  190 
SOF100       155 ASN---N-SNKVTSTEAETPMMDVEQYTVDKKDSSVTQTDDK-----------KLLKIRR  199 
 
SOF90     181 DGNE-KTRDLYDVKREVKDNGDGTLDVTLK-VTPKQIDEGADVMALLDVSKKMTKENFDK  238 
SOF90     181 DGNE-KTRDLYDVKREVKDNGDGTLDVTLK-VTPKQIDEGADVMALLDVSKKMTKENFDK  238 
SOF13     170 DGNE-KTRDLYDVKREVKDNGDGTLDVTLK-VTPKQIDEGADVMALLDVSKKMTKENFDK  227 
sof75       179 DDNP-KDKDLFDVKREVKDNGDGTLDVTLK-VMPKQIDEGADVMALLDVSQKMTKENFDK  236 
sof22              179 DDNP-KDKDLFDVKREVKDNGDGTLDVTLK-VMPKQIDEGADVMALLDVSQKMTKENFDK  236 
SOF4      187 NRDD-EQRDIVDIKREVKTNADGTIDVTVT-VTPKEIDKGADVMALLDVSKKMTEDDFKN  244 
SOF4     187 NRDD-EQRDIVDIKREVKTNADGTIDVTVT-VTPKEIDKGADVMALLDVSKKMTEDDFKN  244 
sof2               188 NRDG-KLRDIVDVTRTVKTNEDGTIDVTVT-VKPKQIDEGADVMALLDVSKKMSEDDFNN  245 
SOF4.2     191 NRDG-KQRDIVDVTRTVKTNEDGTIDVTVT-VKPKQIDEGADVMALLDVSKKMTEEDFNN  248 
sof28              191 NRDD-KQRDIVDVTRTVETNEDGLLMFTGNGLKPKQIDEGADVMALLDVSQKMTKENFDK  249 
SOF11     185 NRDG-EQRDIFDIKREVKTNADGTIDVTVT-VTPKEIDKGADVMALLDVSQKMTKENFDK  242 
SOF22     200 --DG-EQRDIFDIKREVKTNSDGTIDVTVT-VTPKEIDKGADVMALLDVSKKMTEEDFKN  255 
SOFSTNS554    191 -RDG-EQRDIFDIKREVKTNADGTIDVTVP-VTPKEIDKGADVMALLDVSKKMTEDDFNN  247 
SOF76     192 NRDG-EQRDIVDIKREVKDNGDGTLDVTLK-VTPKEIDKGADVMALLDVSKKMSEDAFNN  249 
sof63              188 NRDG-EQRDIFDIKREVKTNADGTIDVTVT-VTPKEIDKGADVMALLDVSKKMSKEDFNN  245 
sof49              191 DVDNPKDKDLFDVKREVKDNGGGTLDVTLK-VTPKQIDGGADVMALLDVSKKMTQENFDK  249 
SOF100       200 DGDE-KTRDLYDVKREVKDNGDGTIDVTLK-VTPKQIDEGADVMALLDVSQKMTRENFDK  257 
 
SOF90     239 AKEQIKKMVTTLTGEPTDGKE----NHNRRNSVRLMTFYRKVNDPIELT---TKNVDAKL  291 
SOF90     239 AKEQIKKMVTTLTGEPTDGKE----NHNRRNSVRLMTFYRKVNDPIELT---TKNVDAKL  291 
SOF13     228 AKEQIKKMVTTLTGEPTDGKE----NHNRRNSVRLMTFYRKVNDPIELT---TKNVDAKL  280 
sof75              237 AKEQIKKMVTTLTGEPTDGKE----NHNRRNSVRLMTFYRKVSDPIELT---TKNVDAKL  289 
sof22              237 AKEQIKKMVTTLTGEPTDGKE----NHNRRNSVRLMTFYRKVSDPIELT---TKNVDAKL  289 
SOF4      245 AKDKIKKLVKTLTSKSASNSDNDEHKHNSRNSVRLMTFYREISDPIDISGKTDAELDELL  304 
SOF4     245 AKDKIKKLVKTLTSKSASNSDNDEHKHNSRNSVRLMTFYREISDPIDISGKTDAELDELL  304 
sof2               246 AKNKIKKLVKTLTSKSASNSDNDEHKYNSRNSVRLMTFYREISNPIDISGKTEEQLDKLL  305 
SOF4.2     249 AKEKIKKLV-TLTG--T-GKNGGE--HKARNSVRLMTFYREISKPIDISGKTEEQLDTLL  302 
sof28               250 AKEQIKKMVTTLTGEPTDGKE----NHNRRNSVRLMTFYRKVNEPIELT--AENVDKTLL  302 
SOF11     243 AKEQIKKMVTTLTGEPTDGKE----NHNRRNSVRLMTFYRKISEPIDLSGKTSEEVDKEL  298 
SOF22     256 AKDKIKKLVKTLTSKSVSKSTDSQPNHNARNSVRLMTFYREISDPIDISGKTDDELDKLL  315 
SOFSTNS554  248 AKDKIKKLVTTLT----SKSADGQQNLNNRNRVRLMTFYREISDPIDI-GKTETQLDQLL  303 
SOF76     250 AKEKIKQLVTTLTSKSASNSDNDEHKHNSRNSVRLMTFYRKVNEPIEL---TAENVDKTL  306 
sof63              246 AKTKIKQLVKTLTEK------NGE-NHNSRNSVRLMTFYREISDPIDISGKTEEQLDKIL  298 
sof49              250 AKGQIKKVVTTLTGESTDGKG----NYNRRNSVRLMTFYRKVSDPIELTTKT---IGAKL  302 
SOF100       258 AKEQIKKMVTTLTGEPTDGKE----NHNRRNSVRLMTFYREISDPIDISGKTDEELNSIL  313 
 
SOF90     292 NEFWEQAKK-DWDWGVDLQGAIHKAREIFKN---EKNSK--KRQHIVLFSQGESTFSYDI  345 
SOF90     292 NEVWEQAKK-DWDWGVDLQGAIHKAREIFKN---EKNSK--KRQHIVLFSQGESTFSYDI  345 
SOF13       281 NEVWEQAKK-DWDWGVDLQGAIHKAREIFKN---EKNSK--KRQHIVLFSQGESTFSYDI  334 
sof75              290 KEVWDQAKK-DWDWGVDLQGAIHKAREIFKK---EKKSK--KRQHIVLFSQGESTFSYDI  343 
sof22              290 KEVWDQAKK-DWDWGVDLQGAIHKAREIFKK---EKKSK--KRQHIVLFSQGESTFSYDI  343 
SOF4      305 DKLRQEAK-DEYDWGVDLQGAIHKAREIFKK-DQEK--KSGKRQHIVLFSQGESTFSYDI  360 
SOF4     305 DKLRQEAK-DEYDWGVDLQGAIHKAREIFKK-DQEK--KSGKRQHIVLFSQGESTFSYDI  360 
sof2               306 DDLRKKAK-ANYDWGVDLQGAIHKAREIFNK---EKEKKFGKRRHIVLFSQGESTFSYEL  361 
SOF4.2     303 NKLRQEAK-DEYDWGVDLQGAIHKARDVFNK---EKEKESKKRQHIVLFSQGESTFSYDI  358 
sof28              303 DEVWKKAK-EDWDWGVDLQGAIHKAREIFNK---EKEKKSGKRQHIVLFSQGESTFSYDI  358 
SOF11     299 DNIWDKVKKEDWDWGVDLQGAIHKARDIFKK---EKESK--KRQHIVLFSQGESTFSYDI  353 
SOF22     316 DELRKKAK-ANYDWGVDLQGAIHKARTVFKNENNDNKKKSGKRQHIVLFSQGESTFAYEL  374 
SOFSTNS554    304 DELREKAK-ANYDWGVDLQGAIHKAREIFKR-DQEK--KSGKRQHIVLFSQGESTFSYDI  359 
SOF76     307 DEVWKKAK-EDWDWGVDLQGAIHKAREIFNK---EKEKNSGKRQHIVLFSQGESTFSYDI  362 
sof63              299 NDLRKKAK-ANYDWGVDLQGAIHKAREIFKR-DQEK--KSGKRQHIVLFSQGESTFSYDI  354 
sof49              303 EEVWEQAKKD-WDWGVDLQGAIHRARDIFRG---EKGSK--GRQHIVLFSQGESTFSYDI  356 
SOF100       314 DDVWKKAKKD-WDWGVDLQGAIHKARDIFKN---EKNSK--KRQHIVLFSQGESTFSYEL  367 
 
SOF90     346 NANS---KANLKAITEDKITTSNPLLPWLPIFNHTNRKAEIINDVEKVLNMAEKLGIKLP  402 
SOF90     346 NANS---KANLKAITEDKITTSNPLLPWLPIFNHTNRKAEIINDVEKVLNMAEKLGIKLP  402 
SOF13         335 NANS---KANLKAITEDKITTSNPLLPWLPIFNHTNRKAEIINDVEKVLNMAEKLGIKLP  391 
sof75                344 HNKSD--SKILKTRVNENITTSNPLFPWLPIFNHTNRKADMIDDVKYLIKWGEKLGIEGL  401 
sof22              344 HNKSD--SKILKTRVNENITTSNPLFPWLPIFNHTNRKADMIDDVKYLIKWGEKLGIEGL  401 
SOF4      361 KNK--NDRTVTKTRITEKVTTSNPLLPWPPIFNHTNQNEDMLDDFAKLVNKLKSLGLDSL  418 
SOF4     361 KNK--NDRTVTKTRITEKVTTSNPLLPWPPIFNHTNQNEDMLDDFAKLVNKLKSLGLDSL  418 
sof2               362 QNSV-REDKTKLSRLSGAVTSSNPLLPWPPIFNHTHKNIDMLDDVKNLVKLGQTLGIAGL  420 
SOF4.2     359 KN----KDDKKLQKTLTTVTTSNPLFSWLPIFDHTNRKADMIDDIKYLIKWGEALGIEGL  414 
sof28              359 KN---KM-ILQKLPITEKVTTSSPLFPWLPIFNHTNRKAEIIGDLEKVLDMAEKVGISLP  414 
SOF11     354 NDKD-KNNTVRKNRITGKVTTSNPLLPWLPIFNHTNQKAEVIDDVDKLLDFAEKMGISLP  412 
SOF22     375 QYGVKKDTSKLSRLTE-TVTSSNPLLPWPPIFDHTHKNGDILNDVRHLISFADRLGIKSL  433 
SOFSTNS554     360 KN--KNDSKLKKARLT-TVTTSNPLFSWFPIFDHTNRKADMLDDFDKLLSIAQKFGVEIP  416 
SOF76     363 ND--KKDSKLTKSRITGKVTSSNPLLRWPPILEHTHKNGDMINDVKTLIAFASKLGIKKL  420 
sof63              355 KN--KNDSTVTKTRITEKVTTSNPLLPWPPIFDHTHQNADMLEDSAKLIKKLKSLGLESL  412 
sof49              357 SD-KDNGASVRVPSITGNVTASNPLFPWLPIFPPTPHPAEVIDDVDKLLGFAENLGISLP  415 
SOF100       368 D--K---SKLSK-SSLTEVTTSNPLLHWPPIFNYTNRKADMLDDITKVIKKVKDLGVKSV  421 
 
SOF90     403 KGLKTAVQTVGATNAAFGSLLGGG-LTQYLALKEYSS-DNLDGGGFDYSKRVGEGYYYHS  460 
SOF90     403 KGLKTAVQTVGATNAAFGSLLGGG-LTQYLALKEYSS-DNLDGGGFDYSKRVGEGYYYHS  460 
SOF13         392 KGLKTAVQTVGATNAAFGSLLGGG-LTQYLALKEYSS-DNLDGGGFDYSKRVGEGYYYHS  449 
sof75              402 NDLDNTLKLAGAASGIVGGFLGGGSLTEYLSLKEYQS-DRLNASQFNYERRVGEGYYYHS  460 
sof22              402 NDLDNTLKLAGAASGIVGGFLGGGSLTEYLSLKEYQS-DRLNASQFNYERRVGEGYYYHS  460 
SOF4      419 KTVDSVLQVLR-ATSSVGKLLG-QSLTEYLTLSEYNS-DKLGSEWFDYTKRVGEGYYYHS  475 
SOF4     419 KTVDSVLQVLR-ATSSVGKLLG-QSLTEYLTLSEYNS-DKLGSEWFDYTKRVGEGYYYHS  475 
sof2               421 DNLQSTLSLISTGSSLAGAFLGGGSLTEYLTLKEYKS-GDLKENQFDYTKRVGEGYHFHS  479 
SOF4.2     415 SGLKDKLSLAGLASSALGGLFGGGSLTEYLSLKEYQS-DSLKADQFNYEKRVGEGYYYHS  473 
sof28              415 SSLKSAVKVLGLTNSAIGSILG-KGLTEYLGLTEYSS-DNLDGGGFDYSKRVGEGYYYHS  472 
SOF11     413 KGLRAGVQAIGLSNSFLSTFTG-SGLTEYLTLNEYGS-DILKEKQFDYTKRVGEGYYYHS  470 
SOF22     434 SWLKAPLDAISIGNGLFGSVLGGPGLGEYLTLKEYNS-RKLNEDQFDYTKRVGEGYHYHS  492 
SOFSTNS554     417 NGLKTGLKAAATTNSLLSSFTGGDGLTDYLTLREYMA-DKLQETDFNYSNRVGEGYHHHS  475 
SOF76     421 SWIEAPLSMLSLTNDLFGSVLGGGGPGEYLTLTEYDS-HKLNEDQFDYTKRVGEGYHYHS  479 
sof63              413 QTADNILQALQAAN-RIGSLFG-KSPTEYLTLNEYDS-NKLGEESFDYSKHVGEGYYYHS  469 
sof49              416 KGLREGVTAIGLRRGLLSSFTGSG-LTEYLTLSEYGS-AILYYAQFDYTTRVGEGYYYHS  473 
SOF100       422 GTAESVLTALKAMNSLGSFFTGS--LTEYITLKEYDSDKLLEEKYFDYTKRVGEGYYYHS  479 
 
SOF90     461 FSERTHEDKMPLESAIREALKTSVPKLS----DTWFFGILNSFVDK-DTVEKAKLDVIMQ  515 
SOF90     461 FSERTHEDKMPLESAIREALKTSVPKLS----DTWFFGILNSFVDK-DTVEKAKLDVIMQ  515 
SOF13         450 FSERTHEDKMPLESAIREALKTSVPKLS----DTWFFGILNSFVDK-DTVEKAKLDVIMQ  504 
sof75              461 FSER-KTAEMPNRALIKKQLEGLFKGKE----GKWFKSILEKLSLT-DDYQKAKEEAILK  514 
sof22              461 FSER-KTAEMPNRALIKKQLEGLFKGKE----GKWFKSILEKLSLT-DDYQKAKEEAILK  514 
SOF4      476 FSDRESENTMPLENEIKTALKTYLPKFE---EKSWFTNVLKYFELE-EKAEQAKLDVIMK  531 
SOF4     476 FSDRESENTMPLENEIKTALKTYLPKFE---EKSWFTNVLKYFELE-EKAEQAKLDVIMK  531 
sof2               480 FSERKKTGEIPFKSEIEPKIKELFENNKNNQDKSWTEWIFDKLSLT-ERIQKAKQETLMK  538 
SOF4.2     474 FSKRE-TADMPNRDLIKQNLEGLFKE----KDGNWFKSILDKLSLT-DKYQKAKEAALLK  527 
sof28              473 LSDRKYENTMPLEEAIRTALASNFPKLT----DNWFFDILNSFVNK-DTVEKAKLDVIMK  527 
SOF11     471 YSKRTHGDKMPFEKQIREVLEQFLPKIE---SREWAKKFIDIFGLQGQKVDQIGVDVIMK  527 
SOF22     493 FSNRNSEDNMPLESELKKVLETYLPKFKE---ENWFTSVLQYFGLKEKAEQ-TKLDVIMK  548 
SOFSTNS554     476 FSERNTHD-MPMKETLEKLLDSQIPRLGK---ESWFGWALDKLSLTETYRN-GQKAALMK  530 
SOF76     480 FSNRESEDRIPLETEIKEALKAALPRFDE---NNWFTKVLTYFKLKDKAEQ-AKLDIIMK  535 
sof63              470 FSDRKSENTMPLESAIKTALTSNFPKIP----DSWFFGILKSSDIKAKVEK-AKLDVIMQ  524 
sof49              474 YSVRTHGDMLPFESEIRKALEQVLPKIED---REWAPMFIDIFGLPIQKVNQSGIDVIMK  530 
SOF100       480 FSNREYNAEMPFERELKLALETALSSVG----EDWFTSILNRLGLKKETEK-AKVDIIMK  534 
 
SOF90     516 VLNSIFYKREYRYYNHNLSAIAEAKMAQKEGITFYSVDVTSLAK--SKR----------S  563 
SOF90     516 VLNSIFYKREYRYYNHNLSAIAEAKMAQKEGITFYSVDVTSLAK--SKR----------S  563 
SOF13        505 VLNSIFYKREYRYYNHNLSAIAEAKMAQKEGITFYSVDVTSLAK--SKR----------S  552 
sof75              515 VLDYFFYKRDYIYYNHNLSAIAEAKMAQQEGVTFYSVDVTDFNS-ASKRAKRQVKSEEDK  573 
sof22              515 VLDYFFYKRDYIYYNHNLSAIAEAKMAQQEGVTFYSVDVTDFNS-ASKRAKRQVKSEEDK  573 
SOF4      532 VLKSVFYKRQYYYYNHNLSAIAEAKMAQQEGITFYSVDVTSLAK--SNRSKRSSEKTEAD  589 
SOF4     532 VLKSVFYKRQYYYYNHNLSAIAEAKMAQQEGITFYSVDVTSLAK--SNRSKRSSEKTEAD  589 
sof2               539 LLEYLFYKREYHYYNHNLSAIAEAKMAQQEGITFYSVDVTDLKTT-SKRVKRQVESTEDK  597 
SOF4.2     528 VLDYLFYKREYHYYNHNLSAIAEAKMAHR--ASPLLVDVTDLT----ARVKRQTATYTDD  581 
sof28              528 VLNSIFYKKEYRYYNHNLSAIAEAKMAQQEGITFYSVDVTDLNS-ASKRVRRQAAVRKGT  586 
SOF11     528 VINSIFYSRQYYYYNHNLSAIAEAKMAQEEGITFYSVDVTDLKP---KRAKRQAAVLQKT  584 
SOF22     549 VIKSVFYKRQYHYYNHNLSAIAEAKMAQEEGITFYSVDVTDFSS-ALKRAKRQVESEKSR  607 
SOFSTNS554   531 ILDYLFYKREYVYYNHNLSAIAEAKMAQQEGITFYSVDVTDFETT-SKRVKRQVGVLQET  589 
SOF76     536 VIKSVFYKRQYHYYNHNLSAIAEAKMAQKEDITFYSVDVTSPKQADNKRTRRSADTPGE-  594 
sof63              525 VLKSIFYKREYRYYNHNLSAIAEAKMAQKDGITFYSVDVTSPNQPATT--KRSRRSTE--  580 
sof49              531 VINSIFYSRQYFYYNRNLSAIAEAKMAQEEGITFYSVDVTDLSSA-SKRAKRQTAVPQKT  589 
SOF100       535 ILNTLFYRRQYHYYNHNLSAIAEAKMAQEEGITFYSVDVTDLK---PKRAKRQTAVPQKT  591 
 
SOF90     564 KRFSEKTEAEKRND-KFDGYLKEMSEG-KKFLEDKDVVNKDKFKDTLTGLTIKDEFTDKV  621 
SOF90     564 KRFSEKTEAEKRND-KFDGYLKEMSEG-KKFLEDKDVVNKDKFKDTLTGLTIKDEFTDKV  621 
SOF13        553 KRFSEKTEAEKRND-KFDGYLKEMSEG-KKFLEDKDVVNKDKFKDTLTGLTIKDEFTDKV  610 
sof75  574 KKAKEKENIEKKRDEKFDNYSKQMSEGGKEFFNDVDKAEN--FKDTLASVTVTETFGNNV  631 
sof22              574 KKAKEKENIEKKRDEKFDNYLKQMSEGGKEFFNDVDKAEN--FKDTLTSVTVTETFGNNV  631 
SOF4      590 RR-----------NDKFDDYLKKMSEDG-TFLEAKGVENKDKFKDAVTKLTIKDEFSDEV  637 
SOF4     590 RR-----------NDKFDDYLKKMSEDG-TFLEAKGVENKDKFKDAVTKLTIKDEFSDEV  637 
sof2               598 KKEKDREDIEKERNEKFDNYLKQMSEGGKDFFEDVDKA--EKFKDILTNVTVTETFEDGV  655 
SOF4.2     582 KK-KEIEKIEEERNKKFDAYLRKMSEDN-DFLSDVEDK--DKFKDTLTDVTVTETFEDGV  637 
sof28              587 KE--ENKKNEEERNTKFDTYLKKMSEGN-NFLSNVEER--DFFKDTLTELTIKDEFTDKV  641 
SOF11     585 TK----KESEEDRNNKFDEYLKKMSEGGKEFFNDVDEA--DKFKDTLTEVTVTETFENSV  638 
SOF22     608 KKKKIRKTLKENGTEKFDRYLKEMSEG-QNFLNDIDVKNQDKFKDTLTEVKVTETFENSV  666 
SOFSTNS554    590 AKK---EPEKER-NDKFDKYLKDMSEG-KEFLKDID--NQDKFKDILTDVTVTETFEEQV  642 
SOF76     595 -KR----------NEQFAKYLREMSEG-KDFLKNTEIKDKDKFKDTLTELTIKDEFTDKV  642 
sof63              581 KKEAEER------NEKFDKYLKEMSEGGKKFFNDVD--KTDKFKDTLTELKIKDEFTDKV  632 
sof49              590 TKK----ESEEDRNNKFDGYLKKMSEGGKEFFTGVD--KADKFKDTLTELTIKDEFTDKV  643 
SOF100       592 TKK----ESEEDRNNKFDGYLKKMSEGGNAFFNDVD--KADKFKDTLTELTIKDEFTDKV  645 
 
SOF90     622 TVQESSEGKKYHKTSLISETPTVNYT----AAATAKG-----WFSSPTKESLTWTISKEQ  672 
SOF90     622 TVQESSEGKKYHKTSLISETPTVNYT----AAATAKG-----WFSSPTKESLTWTISKEQ  672 
SOF13         611 TVQESSEGKKYHKTSLISETPTVNYT----AAATAKG-----WFSSPTKESLTWTISKEQ  661 
sof75              632 SVESGS-----WKTSLGSNSGSSSRE----VSYKGRDSGSLLSLFGSTKESLTWTISKDQ  682 
sof22              632 SVESGS-----WKTSLGSNSGSSSRE----VSYKGRDSGSLFSLFGSTKESLTWTISKDQ  682 
SOF4      638 NVDKSS-----YELSVGNVRKLDSTT---SINHQPYIP--AGWLASATKESLTWTISKEQ  687 
SOF4     638 NVDKSS-----YELSVGNVRKLDSTT---SINHQPYIP--AGWLASATKESLTWTISKEQ  687 
sof2               656 NVKDNS-----WQVSSENN-NSLHSN-YKSVTHKAASDA-SWWSLYSNKESLTWTISKEQ  707 
SOF4.2     638 NVKENL-----YQTSLDSNSNGSNSNSGGDVRHTKPSGS-SWWTFSGTKESLTWTISKDQ  691 
sof28              642 TVEKDS-----WSKSITDGLKNSNNN---NVKHQQANTS-TWSFFSSSKESLTWTISKEA  692 
SOF11     639 SVENQS-----WKVSSNSN---HKEN----VKYTNAQKN-RNWFSSEVKESLTWTISKEQ  685 
SOF22     667 SVENQ-----SWKVSSNSN----HKE---NVKYTNAKEK--GWFSSEVKESLTWTISKEQ  712 
SOFSTNS554    643 AAGSD-----SWSNSHG------------VVKYQKNENG--GWFTTSKKESLTWTISKEQ  683 
SOF76     643 TVETNSEDKKNYKTNLNEN-----TL---KVNHTPSRAGGWGWLSSTTKE-VHWTISKEQ  693 
sof63              633 TVEENSWNTLSTAGLKNSN----KNK---DVQHQKASQPSVWSFTSPSKESLTWTISKEQ  685 
sof49              644 TVETNSEGK-KNYKTNLKG----NTL---KVNHTPSKAGSLSWFSSATKESLTWTISKDL  695 
SOF100       646 TVENNS-----WNTLSTAG----LKN---SVNHQASSS-SSSWFSRSTKESLTWTISKDQ  692 
 
SOF90     673 -LKTAFESGQPLTLTYKLKVEKEKFKEALQER--SR--KKRAASSESENTVTDTIISNKI  727 
SOF90     673 -LKTAFESGQPLTLTYKLKVEKEKFKEALQER--SR--KKRAASSESENTVTDTIISNKI  727 
SOF13         662 -LKTAFESGQPLTLTYKLKVEKEKFKEALQER--SR--KKRAASSESENTVTDTIISNKI  716 
sof75              683 -LKQAFEEGKPLTLTYKLKVDKDKFRETLKKQQESRRIKKRAASSESENTVTETIISNKI  741 
sof22              683 -LKQAFEEGKPLTLTYKLKVDKDKFRETLKKQQESRRIKKRAASSESENTVTETIISNKI  741 
SOF4      688 -LKEAFEKNGFLTFKYKLQVNKDK----LLKDK-KR--IKRDTSTENKTSVTADIISNTT  739 
SOF4     688 -LKEAFEKNGFLTFKYKLQVNKDK----LLKDK-KR--IKRDTSTENKTSVTADIISNTT  739 
sof2               708 -LKEAFEKNSSLTFKYKLQVNKQK----LLDKNKNR--TKRDTSTENKTSVTKDIISNTV  760 
SOF4.2     692 -LKEAFEKNGFLTFKYKLQVNKDK----LLKDI-KR--TKRGTSTENKTSVTKDIISNTI  743 
sof28              693 -LKETFEKNGSLTFKYKLRVNKDK----LLDLDKKE--TKRDTSTENKTSVTANIISNTV  745 
SOF11     686 -LKQAFEDGKPLTLTYKLKVDNNKLKKALDDKRKNR--PKRSIPTENENSVTEKIISNTV  742 
SOF22     713 -LKEAFEKNSSLTFKYKLRVNKD---KLLDKDKK-R--TKRDTPTEDKTSVTAKIISNTT  765 
SOFSTNS554   684 -LKKAFEDGKPLTFTYKLKVEKDKFKTALEESKKQR--TKRSAPAENENSVTKKIISNTV  740 
SOF76     694 -LKKAFEDGKPLTLTYKLKVDNAKFKKALEENNKKK--TKGDTSTGNKTSVTETIISNTT  750 
sof63              686 -LKEAFEKNGSLTFKYKLRVNKD---KLLDKNKN-I--TKRDTSTEDKTSVTANIISNTI  738 
sof49              696 GRKKAFEDGKPLTLTYKLKVDNGKFKKSLEENNKKR--TKRSAPTENENSIKEKIISNTI  753 
SOF100       693 -LKKAFEDGKPLTLTYKLKVDNNKFKTALEDK-KKR--IKR-LPYRNENSIKEKIISNTI  747 
 
SOF90     728 SYKINNGNDTNDNKNNLEDVKMSYSKFKMPIPELDIEVVVPKVPEKPLVEPMTPLYPAIP  787 
SOF90     728 SYKINNGNDTNDNKNNLEDVKMSYSKFKMPIPELDIEVVVPKVPEKPLVEPMTPLYPAIP  787 
SOF13        717 SYKINNGNDTNDNKNNLEDVKMSYSKFKMPIPELDIEVVVPKVPEKPLVEPMTPLYPAIP  776 
sof75              742 SYKINNGKDTNNNK--LEEVKMSYSKFKMPIPELDIEVVVPQVPEKPLVEPMTPLYPAIP  799 
sof22              742 SYKINNGKDTNNNK--LEEVKMSYSKFKMPIPELDIEVVVPKVPEKPLVEPMTPLYPAIP  799 
SOF4      740 TYKINN-QEVKGNK--LDDVKLTYTKETVPVPDVEGEVVP--IPEKPLVEPMTPLYPAIP  794 
SOF4     740 TYKINN-QEVKGNK--LDDVKLTYTKETVPVPDVEGEVVP--IPEKPLVEPMTPLYPAIS  794 
sof2               761 NYKINN-QEVKGNK--LDDVKLTYTKETVPVPDVEGEVVP--IPEKPLVEPMTPLYPAIP  815 
SOF4.2     744 TYKINE-QKVKGNK--LENVKLTYTKETVPVPDVEGEVVP--IPEKPLVEPMTPLYPAIP  798 
sof28              746 NYKINN-QEVKGNK--LDAVNLTYTKETVPVPDVEGEVVP--IPEKPLVEPMTPLYPAIP  800 
SOF11     743 NYKINK-QEVKGNK--LDDVKLTYTKETVPVPDVEGEVVP--IPEKPLVEPMTPLYPAIP  797 
SOF22     766 TYNINGQE-VKDNK--LDDVNLTYSKFKVPVPQIDGHVIE---PQHRHYLS-PPVTERGP  818 
SOFSTNS554    741 TYKINNQE-VKGNN--LGDVKLTYSKFKVPVPQIDGQVIE---PQAPKLPDLPPVTERGP  794 
SOF76     751 TYKINDQE-VKGNK--LDEVNLTYSKLKVPVPQIDGQVIE---PQAPKLPDLPPVIERGP  804 
sof63              739 TYKINDQE-VKGNN--LDDVNLTYSKFKVPVPQIDGHVIE---PQAPTLPKLPPVIEHGP  792 
sof49              754 TYKINNQKGQTGKK--LDDVSLTYSKLKVPVPQIDEKVIE---QQEPTLPKLPPVIEHGP  808 
SOF100       748 TYKINNQKGQTDKK--LDDVNLTYSKLKVPVPQIDGHVIE---PQAPTLPKLPPVIEHGP  802 
 
SOF90     788 NYPT-----PQLPKDEDLEISGGHGPIVDIVEDTGTGVEGGAQNGVVSTQENKDPIVDIT  842 
SOF90     788 NYPT-----PQLPKDEDLEISGGHGPIVDIVEDTGTGVEGGAQNGVVSTQENKDPIVDIT  842 
SOF13         777 NYPT-----PQLPKDEDLEISGGHGPIVDIVEDTGTGVEGGAQNGVVSTQENKDPIVDIT  831 
sof75              800 NYPT-----PQLPKDEDLEISGGHGPIVDIVEDTGTGVEGGAQNGVVSTQENKDPIVDIT  854 
sof22              800 NYPT-----PQLPKDEDLEISGGHGPIVDIVEDTGTGVEGGAQNGVVSTQENKDPIVDIT  854 
SOF4      795 NYPT-----PQLPKDEDLEISGGHGPIVDIVEDTGTGVEGGAQNGVVSTQENKDPIVDIT  849 
SOF4     795 NYPT-----PQLPKDEDLEISGGHGPIVDIVEDTGTGVEGGAQNGVVSTQENKDPIVDIT  849 
sof2               816 NYPTPDIPTPQLPKDEDLEISGGHGPSVDIVEDTGTGAEGGAQNGVVSTQENRDPIVDIT  875 
SOF4.2     799 NYPT-----PQLPKDEDLEISGGHGPIVDIVEDTGTGVEGGAQNGVVSTQENKDPIVDIT  853 
sof28              801 NYPT-----PQLPKDEDLEISGGHGPIVDIVEDTGAGVEGGAQNGVVSTQENKDPIVDIT  855 
SOF11     798 NYPT-----PQLPKDEDLEISGGHGPIVDIVEDTGTGVEGGAQNGVVSTQENKDPIVDIT  852 
SOF22     819 VLDYTEESIYRLPLEH-----GSNAPDTQVTIEEDTVPQ--RPDILVGGQSGP---VDIT  868 
SOFSTNS554    795 VLDYTEESIYRLPLKH-----GSNAPDTQVTIEEDTVPP--TSDILVGGQSGP---VDIT  844 
SOF76     805 VLDYKEESIYRLPLEH-----GSNAPDTQVTIEEDTVPQ--RPDILVGGQSGP---VDIT  854 
sof63              793 NFEYEEETGYQLPLKH-----GSNAPDTQVTIEEDTVPQ--RPDILVGGQSGP---VDIT  842 
sof49              809 NFEYEEETGYQLPLKH-----GRNAPDTQVTIEEDTVPQ--RPDILVGGQSDP---IDIT  858 
SOF100       803 NFEYEEETGYQLPLEH-----GSNAPDIQVTIEEDTVPQ--RPDILVGGQSGP---VDIT  852 
 
Supplementary Table 1: Forward primers used for PCR construction of SOF site-directed mutants. 
Underlined sequences indicate introduced mutations. For site-directed mutants containing four or more 
mutations not encoded in a single primer, mutations were sequentially introduced using previously 
mutated DNA as a template. 
Introduced mutation Forward Primer 
Alanine substitutions 
K211-Q212-D214-D218/A 5’ CCTTAAAAGTAATGCCTGCAGCAATTGCCGAAGGTGCCGCTGTTATGGCC 3’ 
D218/A 5’ CAAATTGACGAAGGTGCCGCTGTTATGGCCCTTTTAGAT 3’ 
M220/A 5’ GACGAAGGTGCCGATGTTGCGGCCCTTTTAGATGTCTCT 3’ 
D224/A 5’ GATGTTATGGCCCTTTTAGCTGTCTCTCAAAAGATGACA 3’ 
S226/A 5’ ATGGCCCTTTTAGATGTCGCTCAAAAGATGACAAAAGAG 3’ 
K228/A 5’ GCCCTTTTAGATGTCTCTCAAGCGATGACAAAAGAGAATTTTGAT 3’ 
M229/A 5’ GCCCTTTTAGATGTCTCTCAAAAGGCGACAAAAGAGAATTTTGATAAGGCT 3’ 
S226-K228-M229-E232/A  5’GCCCTTTTAGATGTCGCTCAAGCGGCGACAAAAGCGAATTTTGATAAGGC 3’ 
E232/A 5’GCCCTTTTAGATGTCTCTCAAAAGTGACAAAAGCGAATTTTGATAAGGCT 3’ 
S226-K228-M229-E232/A  5’ GCCCTTTTAGATGTCGCTCAAGCGGCGACAAAAGCGAATTTTGATAAGGC 3’ 
K238/A 5’ TGATAAGGCTGCAGAACAAATAAAAAAAATGGTTACAACTTTACAGGC 3’ 
K242/A 5’ GCTAAAGAACAAATAGCAAAAATGGTTACAACTTTAACAGGCGAGCC 3’ 
K243/A 5’ GAACAAATAAAAGCAATGGTTACAACTTTAACAGGCGAGCCA 3’ 
T247-T249/A 5’ AAAATGGTTACAGCTTTAGCAGGCGAGCCAACTGATGGTAAGGAA 3’ 
R262-N263/A 5’ GGTAAGGAAAATCATAATAGGGCTGCTTCTGTACGTCTAATGACT 3’ 
R266/A 5’ CATAATAGGCGTAATTCTGTAGCTCTAATGACTTTTTACCGTAAG 3’ 
M268/A 5’ CGTAATTCTGTACGTCTAGCGACTTTTTACCGTAAGGTTAGC 3’ 
R272/A 5’ GTACGTCTAATGACTTTTTACGCTAAGGTTAGCGATCCGATTGAG 3’’ 
K297/A 5’ GAAGTTTGGGATCAGGCCGCAAAAGATTGGGACTGGGGT 3’ 
D301/A 5’ GATCAGGCCAAAAAAGATTGGGCCTGGGGTGTTGATTTACAAGGC 
D305/A 5’ TGGGACTGGGGTGTTGCTTTACAAGGCGCTATC 3’ 
Q307/A 5’ GACTGGGGTGTTGATTTAGCAGGCGCTATCCATAAGGCT 3’ 
H311/A 5’ GTTGATTTACAAGGCGCTATCGCTAAGGCTCGAGAAATTTTTAAG 3’ 
R326-H328/A 5’ AAGTCAAAAAAAGCCCAAGCTATCGTCCTGTTCTCTCAAGGCGAG 3’ 
S333/A 5’ CATATCGTCCTGTTCGCTCAAGGCGAGTCAACC 3’ 
E336/A 5’ GTCCTGTTCTCTCAAGGCGCGTCAACCTTTAGTTATGAC 3’ 
S337/A 5’ GTCCTGTTCTCTCAAGGCGAGGCAACCTTTAGTTATGACATTCAT 3' 
T361-S363/A 5’ AGGGTAAATGAAAATATCGCAACTGCTAACCCACTGTTTCCCTGG 3’ 
S462-R464/A 5’ GGGTATTATTACCATAGTTTTGCTGAAGCGAAAACTGCTGAAATGCCG 3’ 
N531-S533/A 5’ GACTATATTTACTACAATCACGCTCTCGCAGCAATAGCTGAAGCC 3’ 
E537/A 5’ CTCTCAGCAATAGCTGCAGCCAAAATGGCTCAA 3’ 
K539/A 5’ TCAGCAATAGCTGAAGCCGCAATGGCTCAACAAGAGGGG 3’ 
D552/A 5’ GGGGTCACCTTCTATTCCGTTGCTGTTACTGATTTCAACTCAGCT 3’ 
M597-S598-E599/A 5’ GATAATTACTCAAAACAAGCGGCTGCAGGCGGTAAAGAA 3’ 
K615-D616/A 5’ GTGGATAAGGCAGAGAATTTCGCAGCTACCCTAGCCAGTGTG 3’ 
S679-K680/A 5’ AGTCTCACTTGGACTATTGCCGCAGACCAGTTGAAACAAGCCTTTGAAGAG 3’ 
Y697/A 5’ GGTAAGCCGCTAACCCTCACCGCTAAGCTGAAAGTTGATAAAGAT 3’ 
K698/A 5’ CCGCTAACCCTCACCTATGCGCTGAAAGTTGATAAAGAT 3’ 
L699/A 5’ CCGCTAACCCTCACCTATAAGGCGAAAGTTGATAAAGATAAAGAT 3’ 
V701/A 5’ ACCCTCACCTATAAGCTGAAAGCTGATAAAGATAAATTTAGAGAA 3’ 
L710/A 5’GATAAATTTAGAGAAACTGCTAAAAAGCAACAAGAATCTCG 3’ 
K721/A 5’ GAATCTCGTCGTATAAAGGCACGACGAGCATCTTCGGAAAGT 3’ 
R722/A 5’ GAATCTCGTCGTAAAAAGAAAGCAGCAGCATCTTCGGAAAGTGAG 3’ 
AvrII restriction sites (CCTAGG) 
P148-E149/P-R 5’ GCTAATGCTGAGACTGCACCTAGGATGATGATGGACGTGG 3’ 
K211/R 5’ CCTTAGATGTAACCTTAAAAGTAATGCCTAGGCAAATTGACGAAGGTGCC 3’ 
T230-K231 /P-R 5’GATGTCTCTCAAAAGATGCCTAGGGAGAATTTTGATAAGGC 3’ 
T230-K231-E232/T-L-G  5’ GATGTCTCTCAAAAGATGACCCTAGGGAATTTTGATAAGGCT 3’ 
V285-A286/L-G 5’ CCGATTGAGCTCACTACAAAAAACCTAGGTGCTAAATTAAGG 3’ 
A313-R314-E315-/A-L  5’ GGTGTTGATTTACAAGGCGCTATCCATAAGGCCCTAGGAATTTTTAAGAAAG 3’ 
 
